Category: Press Releases

Drug Delivery, Press Releases

BioNxt Reports Commercialization of ODF Cladribine Product for MS Next Steps

Mar 18, 2024

Based on the recent success of its toxicity and comparative pharmacokinetic (“PK”) studies the Company is advancing towards human comparative bioavailability studies on an expedited...

Continue Reading

Drug Delivery, Featured, Press Releases

BIONXT REPORTS SUCCESSFUL RESULTS FROM ODF CLADRIBINE PK STUDY

Mar 13, 2024

The animal PK study results are highly promising and demonstrated comparable rapid absorption and systemic exposure between the Company’s ODF product and the name-brand reference...

Continue Reading

Drug Delivery, Press Releases

BIONXT REPORTS COMPLETION OF ODF CLADRIBINE PK STUDY

Mar 4, 2024

BioNxt is pleased to report that the comparative pharmacokinetic study for its oral dissolvable film based proprietary Cladribine product for the treatment of Multiple Sclerosis...

Continue Reading

Press Releases

BioNxt Reports Successful Results From ODF Cladribine Toxicity Study

Feb 8, 2024

VANCOUVER, BC – February 7, 2024 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Drug Delivery, Press Releases

BIONXT RECEIVES DELIVERY OF PREMIUM COMMERCIAL COATING AND CUTTING EQUIPMENT FOR COMMERCIAL MANUFACTURING OF DRUG DELIVERY PRODUCTS

Dec 12, 2023

VANCOUVER, BC – December 12, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Drug Delivery, Press Releases

BIONXT ACCELERATES CLADRIBINE ODF CLINICAL AND COMMERCIALIZATION STRATEGY FOR MULTIPLE SCLEROSIS TREAMENT

Nov 20, 2023

VANCOUVER, BC – November 20, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Press Releases

BIONXT REPORTS ON NEW CLADRABINE ODF PRODUCT DEVELOPMENT AND COMMERCIALIZATION PROGRAM

Nov 15, 2023

VANCOUVER, BC – November 15, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Press Releases

BIONXT SIGNS DEFINITIVE AGREEMENT FOR 100% ACQUISITION OF IP AND CO-DEVELOPMENT OF CLADRIBINE ODF DRUG REFORMULATION FOR THE TREATMENT OF MULTIPLE SCLEROSIS

Nov 13, 2023

VANCOUVER, BC – November 13, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTCQB: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Press Releases

BIONXT SIGNS LOI FOR ACQUISITION OF IP AND CO-DEVELOPMENT OF ODF DRUG REFORMULATION FOR NEURODEGENERATIVE DISEASE

Aug 2, 2023

VANCOUVER, BC – August 2, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Press Releases

BIONXT RECEIVES APPROVAL FOR EUROPEAN CLINICAL STUDYOF TRANSDERMAL ROTIGOTINE PATCH FOR PARKINSON’S DISEASE

May 15, 2023

VANCOUVER, BC – May 15, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Press Releases

BIONXT SUCCESSFULLY COMPLETES PILOT STUDY FOR CONTRACT DEVELOPMENT CUSTOMER

May 9, 2023

VANCOUVER, BC – May 9, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...

Continue Reading

Press Releases

BIONXT SECURES CONTRACT TO DEVELOP AND MANUFACTURE ODF PRODUCT FOR INTERNATIONAL PHARMACEUTICAL COMPANY

Apr 24, 2023

VANCOUVER, BC – April 24, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...

Continue Reading